Oncology
HR+ HER2- Early Breast Cancer
Expert Roundtables Podcast: Neoadjuvant Therapy for HR+/HER2- Early-Stage Breast Cancer
Neoadjuvant therapy for HR+/HER2- breast cancer remains one of the more nuanced areas in early breast cancer care. In today’s podcast, Virginia Kaklamani, MD, DSc, Ian Krop, MD, PhD, and Melinda L. Telli, MD, FASCO, explore how they decide when preoperative therapy is appropriate, how they define a meaningful response, and which emerging strategies may reshape practice.
Cardoso F, O’Shaughnessy J, Liu Z, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2– breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(2):442-448. doi:10.1038/s41591-024-03415-7
Dieci MV, Guarneri V, Tosi A, et al. Neoadjuvant chemotherapy and immunotherapy in luminal B-like breast cancer: results of the phase II GIADA trial. Clin Cancer Res. 2022;28(2):308-317. doi:10.1158/1078-0432.CCR-21-2260
Hirmas N, Holtschmidt J, Loibl S. Shifting the paradigm: the transformative role of neoadjuvant therapy in early breast cancer. Cancers (Basel). 2024;16(18):3236. doi:10.3390/cancers16183236
Loi S, Salgado R, Curigliano G, et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(2):433-441. doi:10.1038/s41591-024-03414-8
Mamounas EP, Bandos H, White JR, et al. Omitting regional nodal irradiation after response to neoadjuvant chemotherapy. N Engl J Med. 2025;392(21):2113-2124. doi:10.1056/NEJMoa2414859
Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676-684. doi:10.1001/jamaoncol.2019.6650
Explore More in HR+ HER2- Early Breast Cancer
HR+ HER2- Early Breast Cancer
From Fatigue to Function: Unpacking Multidriver Symptom Clusters in Early-Stage Breast Cancer
HR+ HER2- Early Breast Cancer
